Zimmer Biomet Holdings, Inc. — Q1 2024 Form 10-Q Summary
Business context and reporting period
Zimmer Biomet designs, manufactures and markets orthopedic reconstructive products, sports medicine, biologics, extremities and trauma products, craniomaxillofacial and thoracic products, surgical products, and digital and robotic technologies. The filing covers the unaudited three months ended March 31, 2024, compared with the same period ended March 31, 2023.
Reportable segments are Americas, EMEA and Asia Pacific. Results are seasonal because many products are used in elective surgical procedures.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Net sales | $1,889.2 million | $1,831.0 million | 3.2% increase |
| Operating profit | $265.9 million | $327.3 million | 18.8% decrease |
| Operating margin | 14.1% | 17.9% | Down 3.8 percentage points |
| Net earnings attributable to Zimmer Biomet | $172.4 million | $232.5 million | 25.8% decrease |
| Diluted EPS | $0.84 | $1.11 | 24.3% decrease |
| Effective tax rate | 19.7% | 18.9% | Up 0.8 percentage points |
| Operating cash flow | $228.0 million | $307.7 million | 25.9% decrease |
Sales growth reflected market growth, new product introductions and commercial execution, partly offset by a 1.2% foreign-currency headwind. Volume and mix contributed 4.2% to sales growth, while pricing contributed 0.2%.
- Geography: U.S. sales increased 3.7% to $1,099.2 million; international sales increased 2.5% to $790.0 million.
- Product categories: Knees increased 3.4% to $788.1 million; Hips declined 0.3% to $491.2 million; S.E.T. increased 4.4% to $452.6 million; Other increased 10.6% to $157.3 million.
- Segment performance: Americas operating profit increased to $639.3 million from $608.9 million; EMEA increased to $153.0 million from $149.5 million; Asia Pacific increased to $93.3 million from $90.2 million. These segment measures exclude corporate items and other centrally managed expenses.
- Cash and liquidity: Cash and equivalents were $393.0 million at March 31, 2024, compared with $415.8 million at December 31, 2023. Available committed revolving capacity totaled $2.5 billion, consisting of $1.0 billion under the 364-day facility and $1.5 billion under the five-year facility.
- Debt: Total debt was $5,796.2 million, including $970.0 million classified as current. The $850.0 million of senior notes due November 2024 and $120.0 million outstanding under the uncommitted credit facility comprise the current debt.
- Capital allocation: The company paid $49.4 million of dividends, repurchased $113.6 million of common stock, and declared a quarterly dividend of $0.24 per share. Remaining authorization under the repurchase program was $67.8 million.
Material changes versus the prior comparable period
- Net sales increased $58.2 million, but operating profit declined $61.4 million and net earnings attributable to Zimmer Biomet declined $60.1 million.
- Restructuring and other cost-reduction charges increased to $124.4 million from $41.8 million. The increase primarily reflected the 2023 Restructuring Plan, including $71.0 million of employee termination benefit charges.
- Intangible amortization increased to $142.1 million from $133.4 million, primarily due to 2023 acquisitions and purchased intellectual property and licensing arrangements.
- Interest expense increased to $50.7 million from $48.2 million, primarily due to higher losses on fixed-to-variable interest-rate swaps.
- Operating cash flow decreased by $79.7 million, driven by higher bonus, tax and restructuring payments, timing of accounts-payable payments and other working-capital changes.
- Investing cash outflows increased to $195.0 million from $149.4 million, including investments in instruments, property and equipment, debt securities and intangible assets.
- Financing cash outflows declined to $50.1 million from $206.7 million because the prior-year period included larger share repurchases and debt repayments.
Guidance, outlook, risks and unusual items
Management expects 2024 revenue growth in the mid-single digits, driven by market growth, new products, commercial execution and continued product-supply improvements. Based on recent exchange rates, foreign currency is expected to reduce full-year sales growth by approximately 0.5%. Management expects operating profit to increase in 2024 through higher sales, fixed-cost leverage and restructuring savings, partly offset by higher amortization and restructuring implementation costs. Net interest expense is expected to increase slightly, and income tax expense is expected to rise because favorable tax settlements are not expected to recur.
- The 2023 Restructuring Plan is expected to produce total pre-tax charges of $120 million to $135 million through 2025 and annual gross pre-tax operating-expense savings of $175 million to $200 million by the end of 2025. Approximately $92 million had been incurred through March 31, 2024.
- The 2021 and 2019 restructuring plans had incurred approximately $170 million and $336 million, respectively, through March 31, 2024. The 2019 plan is expected to require approximately $34 million of additional charges and completion of a manufacturing-facility closure in 2025.
- The IRS has proposed adjustments for tax years 2010–2019. The 2013–2015 proposals include an estimated additional 2013 tax expense of approximately $370 million, before interest and penalties. The company disputes the proposed adjustments and does not expect final resolution within the next 12 months.
- Accrued litigation liabilities were $226.5 million at March 31, 2024. Product-liability matters include Durom Cup, Metal Reaction and Biomet metal-on-metal hip implant claims; ultimate losses could exceed current estimates.
- Potential payments under development, distribution and other contractual arrangements range from zero to approximately $405 million, depending on milestones and other events.
- Key risks include pricing pressure, competition, product development and regulatory requirements, supply-chain disruption, cybersecurity, foreign exchange and interest-rate exposure, substantial indebtedness, tax disputes, product liability and intellectual-property litigation, and execution of restructuring and acquisition integration plans.
- Management stated that cash from operations, cash on hand and available revolving capacity should satisfy liquidity requirements for at least the next twelve months. The filing also notes that refinancing conditions and future liquidity needs could change.
Most important facts for investors to verify
- Whether mid-single-digit 2024 sales growth and the approximately 0.5% foreign-currency headwind remain achievable.
- Whether restructuring savings materialize on schedule and offset the remaining restructuring charges and implementation costs.
- How the November 2024 $850.0 million senior-note maturity and the $120.0 million uncommitted-facility borrowing will be refinanced or repaid.
- Progress and potential financial exposure in the IRS tax disputes, particularly the proposed 2013–2015 adjustments.
- Changes in accrued litigation liabilities and developments in the major product-liability matters.
- Whether operating cash flow improves after the Q1 timing effects and elevated restructuring, tax and bonus payments.
- Sales and margin trends by product category and geography, particularly Hips, Asia Pacific and the higher-growth ROSA robotic technology business.